Operational Costs Compared: SG&A Analysis of Amgen Inc. and Summit Therapeutics Inc.

A Decade of SG&A: Amgen Inc. vs. Summit Therapeutics Inc.

In the ever-evolving pharmaceutical industry, operational efficiency is key. Over the past decade, Amgen Inc. and Summit Therapeutics Inc. have showcased contrasting strategies in managing their Selling, General, and Administrative (SG&A) expenses. Amgen, a biotech giant, consistently reported SG&A expenses averaging around $5.3 billion annually, peaking at $6.2 billion in 2023. This reflects a steady growth of approximately 31% from 2014. In contrast, Summit Therapeutics, a smaller player, maintained a modest average of $16.5 million, with a notable increase of over 300% from 2014 to 2023. This stark difference highlights the scale and operational strategies of these companies. While Amgen's expenses underline its expansive operations, Summit's leaner approach may indicate a focus on niche markets or innovative R&D. As the industry faces new challenges, these trends offer insights into how companies balance growth with operational costs.